Investor Relations Latest News InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board April 18, 2024 Read More » InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration April 16, 2024 Read More » InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies April 4, 2024 Read More » InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance March 20, 2024 Read More » View More News Latest Events Water Tower Research Fireside Chat with InMed CEO Eric A. Adams January 25, 2024 Read More » The Microcap Conference 2024 January 30-February 1, 2024 Read More » MJ Biz Con November 28 – December 1, 2023 Read More » 12th World Congress on Itch (WCI) 2023 November 7, 2023 Read More » View More Events Stock Information NASDAQ:INM stock price by TradingView See Stock Information Presentations Corporate Presentation – April 2024 View Presentation View All Presentations Latest Financial Reports 2024 Q1 Quarterly Press Release 10-Q Q2 Quarterly Press Release 10-Q View All Financial Reports Latest SEC Filings Investor Alerts Sign up for investor alerts! Sign Up Information Request Send us a request for information Learn More
InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board April 18, 2024 Read More »
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration April 16, 2024 Read More »
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies April 4, 2024 Read More »